期刊文献+

血液透析血管通路狭窄的发生机制及其治疗进展 被引量:27

下载PDF
导出
摘要 血液透析(hemodialysis)成为终末期肾衰竭(end stage renal disease)患者赖以生存的重要手段。然而随着透析生存期延长及患者日趋老龄化,血管通路狭窄(vascular access stenosis)已成为导致血液透析失败的重要原因。研究血管通路狭窄产生的机制,选择合适的治疗方案是摆在透析工作者面前的重要课题。本文拟就血管通路狭窄的机制及治疗研究进展进行综述。
作者 李立 刘必成
出处 《中国血液净化》 2005年第12期669-671,681,共4页 Chinese Journal of Blood Purification
  • 相关文献

参考文献24

  • 1NKF-DOQI Clinical Practice Guidelines for hemodialysis vascular access. Am J Kidney Dis, 1997, 30(supp13):S152-191.
  • 2Sukhatme VP. Vascular access stenosis: Prospects for prevention and therapy. Kidney Int, 1996, 49:1161-1174.
  • 3Joseph S, Adler S. Vascular access problems in dialysis patients: pathogenesis and strategies for management. Heart Dis, 2001, 3(4):242-247.
  • 4LeSar CJ, Merrick HW, Smith MR. Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg, 1999, 189(1):73-79.
  • 5Prakash R, Miller CCⅢ, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis, 1995,26:347-352.
  • 6Murphy GJ, White SA, Nicholson ML. Vascular access for haemodialysis. Br J Surg, 2000, 87:1300-1315.
  • 7Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis, 2001, 37(5):970-980.
  • 8Ikegaya N, Yamamoto T, Takeshita A, et al. Elevated erythropoietin receptor and transforming growth factor β 1expression in stenotic AV fistulae used for hemodialysis.J Am Soc Nephrol, 2000,11:928-935.
  • 9Neville RF, Sidawy AN. Myointimal hyperplasia: basic science and clinical considerations. Sem Vasc Surg, 1998,11:142-148.
  • 10Adler S, Szczech L, Qureshi A, et al. Anticardiolipin antibodies are associated with stenosis of vascular access in patients receiving hemodialysis. Clin Nephrol, 2001,82:368-378.

同被引文献143

引证文献27

二级引证文献130

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部